Joshua Zeidner, MD
Enriched profileAssociate Professor of Medicine; Chief of Leukemia Research; Director of Clinical Cancer Research, Commercial Integration · University of North Carolina at Chapel Hill
Joshua Zeidner is Associate Professor of Medicine; Chief of Leukemia Research; Director of Clinical Cancer Research, Commercial Integration at University of North Carolina at Chapel Hill. OpenAlex indexes 323 publications with 3,930 citations (h-index 28); ClinicalTrials.gov lists 10 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Joshua Zeidner, M.D., is Associate Professor of Medicine at University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center. The public record shows 323 publications with 3,930 citations (h-index 28), centered on Acute Myeloid Leukemia Research, Retinoids in leukemia and cellular processes, Chronic Myeloid Leukemia Treatments. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 27 companies.
- Most recent indexed publication: 2026 · American journal of hematology
- Top research focus: Acute Myeloid Leukemia Research
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 27 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 38 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 57.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML
Sponsor: UNC Lineberger Comprehensive Cancer Center
Industry payments
Updated 16 Oct 2026
27 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Syndax Pharmaceuticals, Inc.Program year202522 payments$19,189openpaymentsdata.cms.gov ↗
- Ipsen InnovationProgram year20256 payments$16,380openpaymentsdata.cms.gov ↗
- Sumitomo Pharma America, Inc.Program year202511 payments$14,870openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
69.2%BCL-2 Inhibitor46.8%Venclexta100%Part D≥73 patientsBCR-ABL tyrosine kinase inhibitors6.5%Scemblix100%Part D<11 patients+ 4 more classes in this area
Anti-infectives
27.8%Azole Antifungal14.5%Posaconazole53%Voriconazole47%Part D≥24 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor7.7%Valacyclovir100%Part D≥20 patients+ 1 more class in this area
Musculoskeletal
3%Xanthine oxidase inhibitor3%Allopurinol100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 16 Oct 2026
96 congress contributions (2014–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- A phase 3 study of olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.
American journal of hematology
Article2026 - Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Journal of clinical oncology
Article2026 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).
American journal of hematology
Article2026
Most-cited works
by citation count (OpenAlex)Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/joshua-zeidner-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
unclineberger.org/people/joshua-zeidner
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unclineberger.org ↗
Mentions by others
where others cite or feature them- Other
vjhemonc.com/speaker/joshua-zeidner
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
New York Medical College
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →unclineberger.org ↗
Editorial & leadership roles
journal and society appointments- Co-chair
Myeloid Clinical Trial Working Group, Hoosier Cancer Research Network
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hoosiercancer.org ↗
Secondary affiliations
appointments beyond the home institution- Hoosier Cancer Research Network
Co-chair, Myeloid Clinical Trial Working Group
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hoosiercancer.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emjreviews.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Lisa Carey, MD
University of North Carolina at Chapel Hill
Diana Perkins, MD
University of North Carolina at Chapel Hill
Norman Sharpless, MD
University of North Carolina at Chapel Hill
Douglas Drossman, MD
University of North Carolina at Chapel Hill
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center